缅北禁地

December 18, 2020

EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
TO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA庐

December 16, 2020

LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study
First Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer

December 10, 2020

BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPAN
If approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimer鈥檚 disease
Aducanumab is now under regulatory review in Japan, Europe and the United States

December 4, 2020

EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

November 30, 2020

EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIES
This collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of伪-synuclein misfolding and aggregation

November 30, 2020

EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

November 27, 2020

AbbVie and Eisai Announce an approval for additional indication of HUMIRA庐, a fully Human Anti-TNF伪 Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world

November 26, 2020

EISAI COMMENCES 鈥淧aDiCo鈥� SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSON鈥橲 DISEASE
WITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS

November 18, 2020

EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME

November 18, 2020

JYSELECA庐 (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN
A once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies

November 16, 2020

EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA庐 FOR USE IN PEDIATRIC PATIENTS

November 10, 2020

LENVIMA庐 Plus KEYTRUDA庐 Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
LENVIMA庐 Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib
Results of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting

November 9, 2020

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer鈥檚 Disease Using Blood
The Content Presented at the 13th Clinical Trials on Alzheimer鈥檚 Disease (CTAD) Conference

November 7, 2020

Update on FDA Advisory Committee鈥檚 meeting on aducanumab in Alzheimer鈥檚 disease

October 30, 2020

European Medicines Agency Accepts Biogen鈥檚 Aducanumab Marketing Authorization Application for Alzheimer's Disease
If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer鈥檚 disease and to meaningfully change the course of Alzheimer鈥檚 disease

October 28, 2020

EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMER鈥橲 DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMER鈥橲 DISEASE CONFERENCE

October 27, 2020

EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORM
Aiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China

October 27, 2020

GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIAL
AMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19

AMGEN鈥橲 APREMILAST AND EISAI鈥橲 ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK

October 26, 2020

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

October 21, 2020

NOTICE REGARDING BIOGEN鈥橲 DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMER鈥橲 DISEASE

October 16, 2020

SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA庐 AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA

October 8, 2020

THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGY
Establishment of Social Cooperation Program 鈥淧rotein Degradation Drug Discovery鈥�

October 6, 2020

INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCE
Adopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)"

September 30, 2020

Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea

September 25, 2020

JYSELECA庐 (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS
Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials

September 23, 2020

EISAI RECEIVES POSITIVE OPINION FROM EMA鈥橲 CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA庐 IN PEDIATRIC PATIENTS

September 23, 2020

Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA庐 (pembrolizumab) Plus LENVIMA庐 (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy

September 18, 2020

EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN庐 (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020

September 17, 2020

EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM

September 11, 2020

EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020

September 7, 2020

EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA庐 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA

August 25, 2020

Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products
EISAI TO LAUNCH SAHNE庐 MEDICAL SPRAY AND SAHNE庐 MEDICAL CREAM
Sahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid

August 25, 2020

EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020)

August 7, 2020

FDA Accepts Biogen鈥檚 Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021
If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer鈥檚 disease

August 6, 2020

EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN

July 30, 2020

APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA庐 FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN

July 28, 2020

EISAI AND DeNA TO PROVIDE SMARTPHONE APP 鈥淓ASIIT APP鈥� THROUGH BUSINESS ALLIANCE AGREEMENT
EISAI DEMENTIA PLATFORM EASIIT COMMENCES

July 27, 2020

EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT

July 22, 2020

EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMER鈥橲 DISEASE AND DEMENTIA AT THE ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020

July 20, 2020

Smartphone app for vital signs measurement of patients with the novel coronavirus infection
Experimental study project adopted as AMED project
Preventing medical infrastructure collapse by a monitoring system linked to LINE

July 14, 2020

INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMER鈥橲 DISEASE

July 10, 2020

INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDED
RESEARCH ACTIVITIES COMMENCE

July 8, 2020

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer鈥檚 Disease
If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer鈥檚 disease

July 8, 2020

Eisai and Merck Receive Complete Response Letter for LENVIMA庐 (lenvatinib) plus KEYTRUDA庐 (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

July 8, 2020

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA

July 8, 2020

NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO庐 ACCEPTED IN HONG KONG
FIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN

July 6, 2020

EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO庐 (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN

July 6, 2020

NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA庐 LAUNCHED IN JAPAN

July 1, 2020

REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVID
GCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORAN鈥橲 INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTION
銆赌銆赌
EISAI鈥橲 ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES

June 29, 2020

Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares

June 25, 2020

EISAI RECEIVES APPROVAL FOR PARKINSON鈥橲 DISEASE TREATMENT EQUFINA庐 IN SOUTH KOREA

June 23, 2020

SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS

June 19, 2020

CONTINUATION OF 鈥淧OLICY FOR PROTECTION OF THE COMPANY鈥橲 CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)鈥�

June 10, 2020

EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICA
SUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM

June 4, 2020

BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL 鈥淣OUKNOW鈩⑩�� TO BE USED IN BEAUTY SALONS

June 2, 2020

EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO鈩� (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA

May 29, 2020

AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA庐, a Fully Human Anti-TNF伪 Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa

May 29, 2020

Results from LENVIMA庐 (lenvatinib) plus KEYTRUDA庐 (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting

May 18, 2020

The effect of SEI-I* evokes the joy of eating
EISAI TO LAUNCH NEW SELBELLE庐 PREMIUM TABLETS AND NEW SELBELLE庐 PREMIUM FINE GRANULES
The first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes

May 14, 2020

EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING

April 27, 2020

EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN 鈥淭HE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING)鈥� BY INSTITUTIONAL INVESTOR MAGAZINE

April 1, 2020

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

March 26, 2020

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA

March 25, 2020

DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 鈥�20

March 23, 2020

EISAI TO LAUNCH DIGITAL TOOL 鈥淣OUKNOW鈩⑩�� IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH)

March 19, 2020

All-case Surveillance Condition for Approval of 鈥淎ctonel庐 17.5 mg tablets鈥� for Treatment of Paget鈥檚 Disease of Bone Cleared in Japan

February 25, 2020

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China

February 21, 2020

EISAI RECEIVES THE PRESIDENT鈥橲 AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDS
FOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA庐

January 30, 2020

EISAI TO SUPPORT COUNTER MEASURES FOR CHINA鈥橲 NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA

January 29, 2020

EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. USING LIQUID BIOPSY TO ACCELERATE NEXT-GENERATION DRUG DISCOVERY AND DEVELOPMENT

January 23, 2020

DAYVIGO鈩� (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPAN
NON-SEDATIVE OREXIN RECEPTOR ANTAGONIST DEMONSTRATES EFFECTIVENESS FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE

January 23, 2020

APPROVAL OF ANTIEPILEPTIC DRUG FYCOMPA庐 IN JAPAN FOR MONOTHERAPY AND PEDIATRIC INDICATIONS FOR PARTIAL-ONSET SEIZURES, AS WELL AS A NEW FORMULATION

January 20, 2020

Eisai Rated 鈥淎鈥�, the highest rating in the CDP Climate Change Report 2019

January 10, 2020

LAUNCH OF ANTICANCER AGENT HALAVEN庐 IN CHINA

January 6, 2020

FYCOMPA庐 FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA